



DNDi @ ASTMH 2011

Drugs for Neglected Diseases *initiative* (DNDi) Presentations
American Society of Tropical Medicine and Hygiene (ASTMH), 60th Annual Meeting
4-8 December 2011, Philadelphia, PA, USA

VISIT THE DNDi BOOTH – Booth # 115

Monday, December 5, 2011

- **POSTER (#318): Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection**
AUTHORS: Zewdu H. Dadi,¹ Workagegnehu Hailu,¹ Teklu Weldegebreal,¹ Hailemariam Tafes,² Raymond Omollo,³ Sisay Yifru,¹ **Manica Balasegaram,**⁴ Asrat Hailu⁵
AFFILIATIONS: 1. University of Gondar, Gondar, Ethiopia; 2. Arbaminch Hospital, Arbaminch, Ethiopia; 3. Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; **4. Drugs for Neglected Diseases *initiative* (DNDi), Geneva, Switzerland;** 5. Addis Ababa University, Addis Ababa, Ethiopia
SESSION TITLE: Poster Session 28. Poster Session A Presentations and Light Lunch
SESSION TIME: 12:00-1:45 PM
LOCATION: Convention Center - Ballroom AB
LINK: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=3e738b4d-67ec-4083-9545-c4f1200bef50&sKey=7cb13c72-f25b-4915-b4f1-c806e3395a85>

Tuesday, December 6, 2011

- **SYMPOSIUM (Session # 84): A Decade Later: Drug Development and the Promise of Health Care Impact**
SESSION TIME: 10:15 AM - 12:00 PM
SPEAKER: Monique Wasunna, DNDi Africa/KEMRI
LOCATION: Convention Center - Room 204A
LINK: <http://www.abstractsonline.com/Plan/ViewSession.aspx?mID=2756&sKey=d00bcb64-222c-40a6-a23f-45b41d7ea22b>
DETAILS:
 - Organizer: Tim Wells, MMV; Co-chair: Elizabeth Ponder (replacing Melinda Moree), BVGH
 - 10:15 AM: The role of PDPs in accelerating development of the right antimalarials for the right populations – Robert Newman, WHO

- 10:35 AM: A successful model to engage biotech companies into drug discovery for global health impact: The Human African Trypanosomiasis (HAT) Drug Discovery Program – Yves Ribeill, SCYNEXIS
 - 10:55 AM: A role for academics? The Global TB Research network – David G. Russell, Cornell University
 - 11:20 AM: PDP Partnering to develop and monitor new treatments for malaria– an industry perspective – Silvio Gabriel, Novartis
 - **11:40 AM: How regional platforms may facilitate innovation and access to new tools: The example of LEAP (Leishmaniasis East Africa) Platform – Monique Wasunna, KEMRI, DNDi**
- **POSTER (#849): Analogues of fenarimol as novel compounds for the treatment of Chagas disease**
AUTHORS: Martine Keenan [presenter],¹ Mike Abbott,¹ Paul Alexander,¹ Tanya Armstrong,² Wayne Best,¹ Bradley Berven,¹ Adriana Botero,² Jason Chaplin,¹ Susan Charman,³ **Eric Chatelain,**⁴ Hugo Diao,¹ **Tom von Geldern,**⁴ Maria Kerfoot,² Andrea Khong,² Joshua McManus,¹ **Ivan Scandale,**⁴ Andrew Thompson,² Zhisen Wang,¹ Karen White³
AFFILIATIONS: 1. Epichem, Perth, Australia; 2. School of Veterinary & Biomedical Sciences, Murdoch University, Perth, Australia; 3. CDCO, Monash University, Melbourne, Australia; **4. Drugs for Neglected Diseases initiative, Geneva, Switzerland**
SESSION TITLE: Poster Session 86. Poster Session C Presentations and Light Lunch
SESSION TIME: 12:00-1:45 PM
LOCATION: Convention Center - Ballroom AB
LINK: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=25fe2a4c-6b0f-4015-87db-ca8d54e1827a&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a>
 - **POSTER (#LB-2171): Plasmodium falciparum polymorphisms and human CYP2C8 polymorphisms in clinical efficacy of artemisinin-based combination therapies in Liberia**
AUTHORS: Sabina Dahlstrom,¹ Vincent Jullien,² Oumou Maiga-Ascofare,¹ Birgit Schramm,³ Joel J. Jones,⁴ Yah M. Zolia,⁴ Elizabeth A. Ashley,³ **Jean-Rene Kiechel,**⁵ Philippe J. Guerin,³ Jacques Le Bras,⁶ Sandrine Houze⁷
AFFILIATIONS: 1. Institut de Medecine et d'Epidemiologie Appliquee, Paris, France; 2. Saint-Vincent de Paul hospital, AP-HP, Paris, France; 3. Epicentre, Paris, France; 4. National Malaria Control Programme, Ministry of Health and Social Welfare, Monrovia, Liberia; **5. Drugs for Neglected Diseases initiative, Geneva, Switzerland**; 6. Paris-Descartes University, IRD UMR216, Paris, France; 7. Parasitology Laboratory French National Malaria Reference Centre, AP-HP, Bichat-C. Bernard Hospital, Paris, France
SESSION TITLE: Poster Session 86. Poster Session C Presentations and Light Lunch
SESSION TIME: 12:00-1:45 PM
LOCATION: Convention Center - Ballroom AB
LINK: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=96cbf729-3cdb-4826-92f5-6cc49c781eb5&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a>
 - **POSTER (#898): A systematic review and meta-analysis of non-randomized and randomized controlled studies of artesunate and amodiaquine for the treatment of uncomplicated falciparum malaria in Africa**
AUTHORS: Piero L. Olliaro,¹ Michel Vaillant,² Michael O. Harhay³
AFFILIATIONS: 1. World Health Organization (WHO), Geneva, Switzerland; 2. Santé, Luxembourg, Luxembourg; 3. University of Pennsylvania, Philadelphia, PA, United States

SESSION TITLE: Poster Session 86. Poster Session C Presentations and Light Lunch

SESSION TIME: 12:00-1:45 PM

LOCATION: Convention Center - Ballroom AB

LINK: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=7a41f7e1-6246-4547-a8de-e5c662f069a4&sKey=e085170f-1e5f-491f-99e6-cf35f6c71b8a>

Wednesday, December 7, 2011

• **SYMPOSIUM (Session # 119): CYP51 as a Target for Chagas Disease Drugs**

SESSION TIME: 8:00 - 9:45 AM

SPEAKER: Isabela Ribeiro, DNDi Latin America

LOCATION: Convention Center - Room 201A

LINK: <http://www.abstractsonline.com/Plan/ViewSession.aspx?mID=2756&sKey=724ec211-b459-44e3-a7b5-252c92b71679>

DETAILS:

- Organizer: James H. McKerrow, UCSF; Co-chair: Larissa Podust, UCSF
- 8:00 AM: CYP51 inhibitors in clinical trials for the etiological treatment of Chagas Disease – Julio Urbina, Venezuelan Institute for Scientific Research
- **8:20 AM: Clinical trial of E1224 for treatment of Chagas disease – Isabela Ribeiro, DNDi**
- 8:40 AM: Crystallography of CYP51 to guide medicinal chemistry – Larissa Podust, UCSF
- 9:00 AM: New drug scaffolds targeting CYP51 in *T. cruzi* – Martine Keenan, Murdoch University, Murdoch, Australia
- 9:20 AM: Optimizing analogs of tipifarnib as *Trypanosoma cruzi* CYP51 inhibitors – Frederick S. Buckner, University of Washington, Seattle

• **POSTER (#1123): Flubendazole as a potential macrofilaricide for field use**

AUTHORS: Charles MacKenzie,¹ Timothy Geary,² Nicole Madrill,¹ Carlos Lanusse,³ **Robert Don⁴**

AFFILIATIONS: 1. Michigan State University, East Lansing, MI, United States; 2. McGill University, Montreal, Canada; 3. Universidad Nacional del Centro, Tandil, Argentina; **4. Drugs for Neglected Diseases initiative, Geneva, Switzerland**

SESSION TITLE: Poster Session 136. Poster Session D Presentations and Light Lunch

SESSION TIME: 12:00-1:45 PM

LOCATION: Convention Center - Ballroom AB

LINK: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2756&cKey=cbe164c8-5e9e-4451-82ab-6155cdf3528e&sKey=d797c0d7-36fb-44f4-bf7f-2ffc82c6078b>

Contacts (on site): Oliver Yun, oyun@dndi.org, +1-646-266-5216; Erin Conklin-Kimaoui, econklin@dndi.org, +1-646-206-2707